Your browser doesn't support javascript.
loading
Integrated compact regulators of protein activity enable control of signaling pathways and genome-editing in vivo.
Franko, Nik; da Silva Santinha, António José; Xue, Shuai; Zhao, Haijie; Charpin-El Hamri, Ghislaine; Platt, Randall Jeffrey; Teixeira, Ana Palma; Fussenegger, Martin.
Afiliación
  • Franko N; Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
  • da Silva Santinha AJ; Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
  • Xue S; Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
  • Zhao H; Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
  • Charpin-El Hamri G; Département Génie Biologique, Institut Universitaire de Technologie, Université Claude Bernard Lyon 1, Villeurbanne, Cedex, France.
  • Platt RJ; Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
  • Teixeira AP; Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
  • Fussenegger M; Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland. fussenegger@bsse.ethz.ch.
Cell Discov ; 10(1): 9, 2024 Jan 23.
Article en En | MEDLINE | ID: mdl-38263404
ABSTRACT
Viral proteases and clinically safe inhibitors were employed to build integrated compact regulators of protein activity (iCROP) for post-translational regulation of functional proteins by tunable proteolytic activity. In the absence of inhibitor, the co-localized/fused protease cleaves a target peptide sequence introduced in an exposed loop of the protein of interest, irreversibly fragmenting the protein structure and destroying its functionality. We selected three proteases and demonstrated the versatility of the iCROP framework by validating it to regulate the functional activity of ten different proteins. iCROP switches can be delivered either as mRNA or DNA, and provide rapid actuation kinetics with large induction ratios, while remaining strongly suppressed in the off state without inhibitor. iCROPs for effectors of the NF-κB and NFAT signaling pathways were assembled and confirmed to enable precise activation/inhibition of downstream events in response to protease inhibitors. In lipopolysaccharide-treated mice, iCROP-sr-IκBα suppressed cytokine release ("cytokine storm") by rescuing the activity of IκBα, which suppresses NF-κB signaling. We also constructed compact inducible CRISPR-(d)Cas9 variants and showed that iCROP-Cas9-mediated knockout of the PCSK9 gene in the liver lowered blood LDL-cholesterol levels in mice. iCROP-based protein switches will facilitate protein-level regulation in basic research and translational applications.